David A. Hoffmann v. First Wave Biopharma, Inc.

CourtCourt of Chancery of Delaware
DecidedSeptember 27, 2023
DocketC.A. 2023-0097-MTZ
StatusPublished

This text of David A. Hoffmann v. First Wave Biopharma, Inc. (David A. Hoffmann v. First Wave Biopharma, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
David A. Hoffmann v. First Wave Biopharma, Inc., (Del. Ct. App. 2023).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

DAVID A. HOFFMAN, ) ) Plaintiff, ) ) v. ) C.A. No. 2023-0097-MTZ ) FIRST WAVE BIOPHARMA, INC., ) a Delaware corporation, ) ) Defendant. )

MEMORANDUM OPINION Date Submitted: June 23, 2023 Date Decided: September 27, 2023

David A. Jenkins, Jason Z. Miller, SMITH, KATZENSTEIN & JENKINS LLP, Wilmington, Delaware; Robert P. Haney, Jr., Garrick D. Josephs, FOLEY HOAG LLP, New York, New York; Peter G. Ellis, Sahar M. Basaria, FOLEY HOAG LLP, Boston, Massachusetts, Attorneys for Plaintiff David A. Hoffman.

Kevin M. Gallagher, Nicole M. Henry, Spencer V. Crawford, RICHARDS, LAYTON & FINGER, P.A., Wilmington, Delaware, Attorneys for Defendant First Wave BioPharma, Inc.

ZURN, Vice Chancellor. Plaintiff David Hoffman is a director of defendant First Wave Biopharma, Inc.

(“First Wave” or the “Company”). Hoffman seeks advancement in connection with

a purported investigation or inquiry into his conduct as a director based on the

Company’s contractual promise to advance fees incurred in connection with

investigations and inquiries.

Hoffman is relatively new to First Wave’s board of directors, and was

appointed in connection with First Wave’s acquisition of a target. That acquisition

resulted in litigation with the target’s stockholder representative followed by

settlement negotiations. First Wave’s plans to raise capital were leaked to the

target’s founder, who used that information to demand a higher settlement payment.

First Wave’s chairman and CEO suspected Hoffman was the mole, and took steps

to create a board committee excluding Hoffman to discuss matters he and the other

directors wanted to keep confidential from the target’s stockholder representative.

Hoffman responded by engaging counsel, and his counsel and First Wave exchanged

letters. At times, First Wave suggested that the other directors believed Hoffman

had breached his fiduciary duties. Hoffman’s counsel asserted that the committee’s

creation amounted to his wrongful exclusion from board discussions.

Notwithstanding the letters, the board approved the committee’s formation.

Hoffman now seeks advancement for his representation in his conflict with

the Company. Hoffman argues that because the other directors concluded that he

1 breached his fiduciary duties, First Wave must have investigated his conduct. First

Wave contends the board acted on a belief that did not result from any investigation.

With the benefit of discovery, the parties proceeded to trial.

The evidence at trial did not prove that the Company undertook any

investigation or inquiry. Rather, it proved that First Wave’s chairman and CEO

presumed that Hoffman disclosed the capital raise, based in part on Hoffman’s

relationship with the target’s founder, and proposed forming the committee based

on that presumption. This opinion concludes Hoffman’s advancement rights are not

triggered because he did not incur expenses in connection with a covered

proceeding.

In pretrial briefing, Hoffman developed a secondary position that, in claiming

he breached his fiduciary duties and violated other laws, the Company had

threatened a lawsuit or regulatory proceeding. Because the advancement provision

entitles him to recover in connection with threatened proceedings, he argued the

Company is obliged to advance his expenses. But Hoffman failed to adequately

plead a claim based on this theory, failed to give the Company adequate notice of

his intent to litigate it, and failed to seek leave to amend his pleading to include it.

These failures defeat his claim for advancement under that theory.

2 I. BACKGROUND

In this post-trial opinion, I have found the following facts by a preponderance

of the evidence based on the witnesses’ videotaped depositions, contemporaneous

documents, and other filings in the record.1

A. The Company’s Acquisition Of Old First Wave Devolves Into Litigation.

Nonparty Dr. Gary Glick founded nonparty First Wave Bio, Inc. (“Old First

Wave”),2 “a clinical-stage biotechnology company specializing in the development

of novel, gut-targeted, small molecule therapies for auto-immune inflammatory

bowel diseases (IBD) and other serious conditions.”3 Glick approached his

long-time friend Hoffman with an opportunity to invest in Old First Wave, which

Hoffman accepted.4

In 2021, AzurRx BioPharma, Inc. (“AzurRx”) acquired Old First Wave for

approximately $18 million in cash, $4 million in stock, and up to $207 million in

1 Level 4 Yoga, LLC v. CorePower Yoga, LLC, 2022 WL 601862, at *2 (Del. Ch. Mar. 1, 2022). That record is sparse: it comprises forty-seven exhibits and the deposition transcripts of Hoffman and First Wave’s chairman and CEO, James Sapirstein. Citations in the form “[Last Name] —” refer to the deposition testimony of the referenced deponent, available at docket item (“D.I.”) 28. Citations in the form “JX —” refer to the parties’ joint trial exhibits. 2 Hoffman 20. 3 JX 1.0083. 4 Hoffman 19–20. 3 milestone payments.5 Additionally, the holders of a majority of Old First Wave’s

outstanding stock at the time of closing had the right to elect a director to the

post-closing entity’s board.6 Practically, Glick had the power to appoint that

director, and in April 2022, he caused Hoffman to be appointed.7 After closing,

AzurRx changed its name to First Wave Biopharma Inc.8

The transaction did not age well. Within two months of closing, Old First

Wave’s stockholder representative Fortis Advisors LLC (“Fortis”) sued First Wave,

alleging it failed to pay part of the up-front consideration and failed to provide notice

that a milestone was met.9 The parties settled that lawsuit on November 15.10 On

May 19, 2022, Fortis sued again, alleging First Wave missed a required payment

under the settlement agreement.11 The parties entered into settlement discussions

and were close to signing a term sheet that contemplated the Company paying Fortis

$1.5 million.12

5 JX 1.0002. 6 JX 1, Ex. 2.1 § 6.9. 7 Hoffman 25–26, 28; D.I. 30 § III ¶¶ 2, 7. 8 D.I. 30 § III.a ¶ 4; First Wave BioPharma, Inc., Form 8-K (Current Report) (Sept. 21, 2021), Ex. 3.1. 9 Fortis Advisors LLC v. First Wave BioPharma, Inc., C.A. No. 2021-0936-JRS, at D.I. 1 (Oct. 29, 2021). 10 First Wave BioPharma, Inc., Form 8-K (Current Report) (Nov. 16, 2021). 11 JX 6. 12 See Sapirstein 37–38. 4 Meanwhile, the Company sought to raise additional capital.13 At a June

meeting of First Wave’s board of directors (the “Board”), First Wave’s directors

discussed potential financing options, including raising between $1 million and $3

million through an equity offering.14 A final decision was not reached at that time.

On July 28 or 29, the Company’s chairman and CEO James Sapirstein informed the

other directors on a Board call that the Company would be raising $4 million through

an at-the-market, or “ATM,” offering.15 The Board did not intend to publicly

disclose the offering until September or October.16

But Glick found out about First Wave’s planned influx of cash almost

immediately. On a July 29 call, Glick informed First Wave representatives that he

was aware the Company was poised to raise $4 million through an ATM offering,

and demanded that the settlement payment to Fortis be increased by $1 million, to a

total of $2.5 million.17 First Wave gave in, and the parties revised and signed the

13 See JX 7.0003. 14 Id. 15 Sapirstein 180. 16 Id. at 38–39. 17 Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Michelson v. Duncan
407 A.2d 211 (Supreme Court of Delaware, 1979)
Levy v. HLI Operating Co., Inc.
924 A.2d 210 (Court of Chancery of Delaware, 2007)
Miller v. Hob Tea Room
75 A.2d 577 (Court of Chancery of Delaware, 1950)
In Re Deputy
962 A.2d 916 (Supreme Court of Delaware, 2008)
Emerald Partners v. Berlin
726 A.2d 1215 (Supreme Court of Delaware, 1999)
Klein v. Sunbeam Corp.
94 A.2d 385 (Supreme Court of Delaware, 1952)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
Sassano v. CIBC World Markets Corp.
948 A.2d 453 (Court of Chancery of Delaware, 2008)
Grand Ventures, Inc. v. Whaley
632 A.2d 63 (Supreme Court of Delaware, 1993)
Vichi v. Koninklijke Philips Electronics
85 A.3d 725 (Court of Chancery of Delaware, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
David A. Hoffmann v. First Wave Biopharma, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/david-a-hoffmann-v-first-wave-biopharma-inc-delch-2023.